硝酸異山梨酯 / 單硝酸異山梨酯
Isosorbide Dinitrate / Isosorbide Mononitrate
1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate / 1,4:3,6-dianhydro-D-glucitol 5-nitrate
別名: Isordil · Ismo · Imdur · Isochron · Dilatrate-SR · Monoket · Titradose · ISDN · EV-151 · sorbide nitrate · AHR-4698 · BM-22145 · IS5-MN · isosorbide-5-mononitrate
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Refractory heart failure or in combination with hydralazine or amlodipine in patients unable to tolerate ACE inhibitors | Isosorbide dinitrate at 0.5-2 mg/kg PO twice daily OR isosorbide mononitrate at 0.25-2 mg/kg PO twice daily | PO | twice daily | — | 🌎 NA |
- Refractory heart failure or in combination with hydralazine or amlodipine in patients unable to tolerate ACE inhibitors: Efficacy is unknown. It is unknown if nitrate-free periods are required to prevent nitrate tolerance.
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Adjunctive treatment of heart failure associated with thyroid storm | Isosorbide dinitrate at 0.5-2 mg/kg PO q8-12h | PO | q8-12h | — | 🌎 NA |
| Refractory heart failure or in combination with hydralazine or amlodipine in patients unable to tolerate ACE inhibitors | Isosorbide dinitrate at 0.5-2 mg/kg PO twice daily OR isosorbide mononitrate at 0.25-2 mg/kg PO twice daily | PO | twice daily | — | 🌎 NA |
- Adjunctive treatment of heart failure associated with thyroid storm: Start at lowest level and titrate upward.
- Refractory heart failure or in combination with hydralazine or amlodipine in patients unable to tolerate ACE inhibitors: Efficacy is unknown.
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
概覽
硝酸異山梨酯 (ISDN) 和單硝酸異山梨酯 (ISMN) 是有機硝酸鹽，作為強效的靜脈擴張劑，主要用於降低心臟前負荷。雖然在人類醫學中廣泛用於心絞痛和充血性心力衰竭 (CHF)，但在小動物醫學中的臨床經驗和療效證據仍然有限。它們偶爾被用作難治性心力衰竭的輔助治療，或用於無法耐受 ACE 抑制劑的病患。與人類相比，犬隻似乎需要高得多的劑量才能達到治療性的血流動力學效果。持續使用可能導致硝酸鹽耐受性。
作用機制
Organic nitrates act as prodrugs that donate nitric oxide (NO) to vascular smooth muscle, leading to profound vasodilation (predominantly venous, with some arterial effects at higher doses).
Mechanism Pathway: Organic Nitrate → converted to free radical Nitric Oxide (NO) → activates soluble guanylate cyclase (sGC) → increases intracellular cyclic GMP (cGMP) → activates Protein Kinase G (PKG) → decreases intracellular calcium and dephosphorylates myosin light chain → Vascular Smooth Muscle Relaxation.
- Hemodynamic Effects: By dilating the venous capacitance vessels, nitrates significantly decrease venous return to the heart (reduced preload), which lowers ventricular filling pressures and helps alleviate pulmonary edema in CHF.
- Additional Effects: Nitrates functionally antagonize acetylcholine, norepinephrine, and histamine. They also relax non-vascular smooth muscle, including biliary, bronchial, gastrointestinal, ureteral, and uterine tissues.
安全性與警告
禁忌症
- Cardiogenic or hypovolemic shock
- Severe hypotension
- Hypovolemia
- Use as a sole agent for treating heart failure
- Concurrent use with selective phosphodiesterase inhibitors (e.g., sildenafil)
不良反應
- Postural hypotension
- Reflex tachycardia
- Lethargy or weakness (secondary to hypotension)
- Gastrointestinal upset
- Restlessness
- Headache (well-documented in humans, difficult to assess in animals)
- Hypersensitivity reactions (rare)
注意事項
Hemodynamic Warning: Use with extreme caution in patients with low blood pressure or uncorrected hypovolemia.
- Nitrate Tolerance: Continuous exposure may lead to tolerance. Consider dosing strategies that allow for a nitrate-free interval if chronic use is intended.
- Laboratory Interference: Serum cholesterol levels may be falsely decreased by nitrates when using the Zlatkis-Zak color reaction method.
- Pregnancy: FDA Category C. Use only if the potential benefit justifies the potential risk to the fetus.
藥物相互作用
Possible additive hypotensive effects; monitor blood pressure closely.
Possible additive hypotensive effects due to alpha-adrenergic blockade.
Concurrent use with sildenafil can cause profound, life-threatening hypotension and is strictly contraindicated. Use with pimobendan (a PDE3 inhibitor) is common in vet med but requires monitoring for excessive vasodilation.
監測
- Clinical efficacy (improvement in respiratory rate/effort, resolution of pulmonary edema)
- Systemic blood pressure (monitor for hypotension)
- Heart rate (monitor for reflex tachycardia)
- Renal values and electrolytes (if used concurrently with diuretics and ACE inhibitors)
藥物動力學
半衰期
吸收
Dogs: Isosorbide mononitrate oral bioavailability is approximately 70%. Oral doses >2 mg/kg yield peak plasma levels >100 ng/mL (believed to be the minimum required for hemodynamic effects). Humans: Both ISDN and ISMN are well absorbed orally; food may delay the rate but not the extent of absorption.
分佈
Widely distributed. Hemodynamic effects require minimum serum concentrations of approximately 100 ng/mL, though some canine studies showed no hemodynamic changes even at much higher peak levels.
代謝
Isosorbide dinitrate undergoes extensive first-pass hepatic metabolism primarily to isosorbide mononitrate. Isosorbide mononitrate is metabolized primarily in the liver but does not undergo first-pass metabolism.
排除
Metabolites do not appear to have pharmacologic activity and are principally excreted in the urine.
過量
Toxicity Profile: Isosorbide mononitrate caused significant lethality in rats and mice at massive dosages (2000 mg/kg and 3000 mg/kg, respectively).
Clinical Signs of Overdose:
- Profound venous pooling
- Decreased cardiac output
- Severe hypotension
- Reflex tachycardia
- Collapse or syncope
Treatment:
- Treatment is primarily supportive.
- Avoid Epinephrine: Drug therapies with agents such as epinephrine are NOT recommended as they may exacerbate the cardiovascular collapse.
- Fluid Therapy: Increasing central fluid volume may be useful to counteract venous pooling, but in patients with pre-existing congestive heart failure (CHF), IV fluids must be administered with extreme caution to avoid precipitating fulminant pulmonary edema.
可用產品
劑型
- Oral tablets
- Sublingual tablets
- Extended-release tablets
- Sustained-release capsules
人用標示
- Isosorbide Dinitrate Oral Tablets: 5 mg, 10 mg, 20 mg, 30 mg, & 40 mg
- Isosorbide Dinitrate Sublingual Oral Tablets: 2.5 mg, & 5 mg
- Isosorbide Dinitrate Extended-Release Oral Tablets: 40 mg
- Isosorbide Dinitrate Sustained-Release Oral Capsules: 40 mg
- Isosorbide Mononitrate Tablets: 10 mg, & 20 mg
- Isosorbide Mononitrate Extended-Release Tablets: 30 mg, 60 mg, & 120 mg
各地核准狀態
暫無法規資料: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Isosorbide dinitrate and standard isosorbide mononitrate tablets should be stored in well-closed/tight containers below 40°C (preferably between 15°-30°C). Isosorbide mononitrate extended-release tablets should be stored between 2°-30°C. Heat and moisture accelerate the loss of potency.
飼主須知
此藥物在獸醫學中的使用經驗有限，通常保留用於晚期或難以治療的心臟疾病。可與食物一起或空腹服用。請嚴格遵守獸醫師的給藥時間表，因為可能需要特定的時間間隔以防止身體對藥物產生耐受性。由於此藥物會降低血壓，請密切觀察您的寵物是否有虛弱、嗜睡、絆倒或昏厥的跡象。如果出現這些情況，請立即聯繫您的獸醫師。請將藥物緊閉於原包裝中，並避免高溫和潮濕，以免藥物失去效力。
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠方最新藥品說明書。